Compare Dicks Sporting Goods Inc (DKS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Dicks Sporting Goods Inc trades at $134.34 (market cap $12.92B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 9.9× Dicks Sporting Goods Inc's market cap, and Dicks Sporting Goods Inc pays a 3.81% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| DKS | VRTX | |
|---|---|---|
Market Cap | $12.92B | $128.16B |
Volume | 2,077,432 | 806,603 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $557.96 |
52-Week Low | $121.15 | $407.37 |
Typical Hold Time | 19 Days | 120 Days |
Enterprise Value | $19.97B | $122.29B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $131.18, down 2.74% on the day, with a bearish technical signal from moving averages and oscillators. The company shows solid profitability with an 18.47% ROE and a net income margin of 3.97%, though recent earnings missed expectations in Q2 2026. Revenue grew to $13.44B in 2025, but profit margins are projected to compress in 2026. A securities class action lawsuit filed for the period September 2025 to August 2026 adds legal overhang.
The stock presents a mixed outlook; strong analyst consensus with a $153.30 price target suggests 17% upside, supported by a reasonable P/E of 14.48. However, near-term risks include the class action litigation, technical bearishness, and margin pressure. The dividend increase to $1.25 signals confidence, but investors must weigh legal and operational headwinds against valuation appeal.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
